GlassScriptPhysician profile
Robin L Allen
NPI 1376052365
$2,472.28
in general payments reported to CMS, 2019-2025
28 companies · $637 in 2025
The $637 reported for 2025 was more than what 94% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.03 · 2022: $442 · 2023: $788 · 2024: $593 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $536.62 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $476.36 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $175.86 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $167.00 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Abbvie INC. | $141.03 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $115.50 | 2022-2025 | Fanapt |
| Lundbeck LLC | $109.31 | 2023-2025 | Rexulti |
| Corium, LLC | $93.18 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $85.31 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Exact Sciences Corporation | $80.02 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $66.49 | 2022-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $59.40 | 2023-2024 | Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $47.31 | 2024-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $43.46 | 2022 | |
| Ironshore Pharmaceuticals INC. | $33.76 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.71 | 2023-2025 | Qelbree, Qelbree |
| Corcept Therapeutics | $29.99 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $26.36 | 2022-2024 | |
| Chiesi USA, INC. | $23.73 | 2021-2022 | |
| Hologic Sales and Service, LLC | $17.72 | 2023 | Thinprep 2000 Processor, Aptima |
| Genzyme Corporation | $15.29 | 2023 | |
| Amgen INC. | $14.78 | 2024 | Repatha, Otezla |
| Noven Therapeutics, LLC | $14.64 | 2024 | Secuado, Xelstrym |
| Neurelis, INC. | $13.95 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $13.56 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2023 | Trintellix |
| Glaxosmithkline, LLC. | $12.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.